Tissue-type plasminogen activator deficiency exacerbates cholestatic liver injury in mice

Hepatology

Volumn 45, Issue 6, 2007, Pages 1527-1537

  Wang, Hongtao ^a   Zhang, Yan ^a,b   Heuckeroth, Robert O ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; TISSUE PLASMINOGEN ACTIVATOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT LIGATION; CELL PROLIFERATION; CHOLESTASIS; CONTROLLED STUDY; ENZYME DEFICIENCY; LIVER INJURY; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ANIMALS; BILE DUCTS; CELL DEATH; CELL DIVISION; CHEMOKINES, CXC; CHOLESTASIS, EXTRAHEPATIC; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FIBRIN; HEPATOCYTE GROWTH FACTOR; HEPATOCYTES; INFARCTION; LIVER; MALE; MICE; MICE, INBRED C57BL; NEUTROPHILS; PLASMIN; RNA, MESSENGER; TISSUE PLASMINOGEN ACTIVATOR; URINARY PLASMINOGEN ACTIVATOR;

EID: 34250157247     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.21613     Document Type: Article

References (54)

1. Miyoshi H, Rust C, Roberts PJ, Burgart LJ, Gores GJ. Hepatocyte apoptosis after bile duct ligation in the mouse involves Fas. Gastroenterology 1999;117:669-677.
2. Ezure T, Sakamoto T, Tsuji H, Lunz JG 3rd, Murase N, Fung JJ, et al. The development and compensation of biliary cirrhosis in interleukin-6-deficient mice. Am J Pathol 2000;156:1627-1639.
3. Gujral JS, Liu J, Farhood A, Jaeschke H. Reduced oncotic necrosis in Fas receptor-deficient C57BL/6J-lpr mice after bile duct ligation. HEPATOLOGY 2004;40:998-1007.
4. Liu Z, Sakamoto T, Ezure T, Yokomuro S, Murase N, Michalopoulos G, et al. Interleukin-6, hepatocyte growth factor, and their receptors in biliary epithelial cells during a type I ductular reaction in mice: interactions between the periductal inflammatory and stromal cells and the biliary epithelium. HEPATOLOGY 1998;28:1260-1268.
5. Bezerra JA, Bugge TH, Melin-Aldana H, Sabla G, Kombrinck KW, Witte DP, et al. Plasminogen deficiency leads to impaired remodeling after a toxic injury to the liver. Proc Natl Acad Sci U S A 1999;96:15143-15148.
6. Canbay A, Higuchi H, Bronk SF, Taniai M, Sebo TJ, Gores GJ. Fas enhances fibrogenesis in the bile duct ligated mouse: a link between apoptosis and fibrosis. Gastroenterology 2002;123:1323-1330.
7. Wang H, Vohra BP, Zhang Y, Heuckeroth RO. Transcriptional profiling after bile duct ligation identifies PAI-1 as a contributor to cholestatic injury in mice. HEPATOLOGY 2005;42:1099-1108.
8. Bergheim I, Guo L, Davis MA, Duveau I, Arteel GE. Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis. J Pharmacol Exp Ther 2006;316:592-600.
9. Eddy AA. Plasminogen activator inhibitor-1 and the kidney. Am J Physiol Renal Physiol 2002;283:F209-F220.
10. Mars WM, Zarnegar R, Michalopoulos GK. Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol 1993;143:949-958.
11. Westergaard UB, Andersen MH, Heegaard CW, Fedosov SN, Petersen TE. Tetranectin binds hepatocyte growth factor and tissue-type plasminogen activator. Eur J Biochem 2003;270:1850-1854.
12. Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nat Med 1999;5:226-230.
13. Huh CG, Factor VM, Sanchez A, Uchida K, Conner EA, Thorgeirsson SS. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc Natl Acad Sci U S A 2004;101:4477-4482.
14. Hwang TH, Yoon BC, Jeong JS, Seo SY, Lee HJ. A single administration of adenoviral-mediated HGF cDNA permits survival of mice from acute hepatic failure. Life Sci 2003;72:851-861.
15. Liu Z, Sakamoto T, Yokomuro S, Ezure T, Subbotin V, Murase N, et al. Acute obstructive cholangiopathy in interleukin-6 deficient mice: compensation by leukemia inhibitory factor (LIF) suggests importance of gp-130 signaling in the ductular reaction. Liver 2000;20:114-124.
16. Joplin R, Hishida T, Tsubouchi H, Daikuhara Y, Ayres R, Neuberger JM, et al. Human intrahepatic biliary epithelial cells proliferate in vitro in response to human hepatocyte growth factor. J Clin Invest 1992;90:1284-1289.
17. Yokomuro S, Tsuji H, Lunz JG 3rd, Sakamoto T, Ezure T, Murase N, et al. Growth control of human biriliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells. HEPATOLOGY 2000;32:26-35.
18. Lin Y, Xie WF, Chen YX, Zhang X, Zeng X, Qiang H, et al. Treatment of experimental hepatic fibrosis by combinational delivery of urokinase-type plasminogen activator and hepatocyte growth factor genes. Liver Int 2005; 25:796-807.
19. Khalil N, Corne S, Whitman C, Yacyshyn H. Plasmin regulates the activation of cell-associated latent TGF-beta 1 secreted by rat alveolar macrophages after in vivo bleomycin injury. Am J Respir Cell Mol Biol 1996;15: 252-259.
20. Yee JA, Yan L, Dominguez JC, Allan EH, Martin TJ. Plasminogen-dependent activation of latent transforming growth factor beta (TGF beta) by growing cultures of osteoblast-like cells. J Cell Physiol 1993;157:528-534.
21. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002;7:d793-d807.
22. Zimmermann A. Regulation of liver regeneration. Nephrol Dial Transplant 2004;19(Suppl 4):iv6-10.
23. Menshikov M, Elizarova E, Plakida K, Timofeeva A, Khaspekov G, Beabealashvilli R, et al. Urokinase upregulates matrix metalloproteinase-9 expression in THP-1 monocytes via gene transcription and protein synthesis. Biochem J 2002;367:833-839.
24. Monea S, Lehti K, Keski-Oja J, Mignatti P. Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J Cell Physiol 2002;192:160-170.
25. Yamanaka H, Obata K, Fukuoka T, Dai Y, Kobayashi K, Tokunaga A, et al. Tissue plasminogen activator in primary afferents induces dotsal horn excitability and pain response after peripheral nerve injury. Eur J Neurosci 2004;19:93-102.
26. Wu YP, Siao CJ, Lu W, Sung TC, Frohman MA, Milev P, et al. The tissue plasminogen activator (tPA)/plasmin extracellular proteolytic system regulates seizure-induced hippocampal mossy fiber outgrowth through a proteoglycan substrate. J Cell Biol 2000;148:1295-1304.
27. Rudnick DA, Perlmutter DH, Muglia LJ. Prostaglandins are required for CREB activation and cellular proliferation during liver regeneration. Proc Natl Acad Sci U S A 2001;98:8885-8890.
28. Sturzebecher J, Prasa D, Hauptmann J, Vieweg H, Wikstrom P. Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine. J Med Chem 1997;40:3091-3099.
29. Gujral JS, Farhood A, Bajt ML, Jaeschke H. Neutrophils aggravate acute liver injury during obstructive cholestasis in bile duct-ligated mice. HEPATOLOGY 2003;38:355-363.
30. Jaeschke H, Farhood A. Neutrophil and Kupffer cell-induced oxidant stress and ischemia-reperfusion injury in rat liver. Am J Physiol 1991;260: G355-G362.
31. Bonder CS, Ajuebor MN, Zbytnuik LD, Kubes P, Swain MG. Essential role for neutrophil recruitment to the liver in concanavalin A-induced hepatitis. J Immunol 2004;172:45-53.
32. Leevy CB, Elbeshbeshy HA. Immunology of alcoholic liver disease. Clin Liver Dis 2005;9:55-66.
33. Li X, Klintman D, Liu Q, Sato T, Jeppsson B, Thorlacius H. Critical role of CXC chemokines in endotoxemic liver injury in mice. J Leukoc Biol 2004;75:443-452.
34. Gujral JS, Liu J, Farhood A, Hinson JA, Jaeschke H. Functional importance of ICAM-1 in the mechanism of neutrophil-induced liver injury in bile duct-ligated mice. Am J Physiol Gastrointest Liver Physiol 2004;286: G499-507.
35. Eastman D, Wurm FM, van Reis R, Higgins DL. A region of tissue plasminogen activator that affects plasminogen activation differentially with various fibrin(ogen)-related stimulators. Biochemistry 1992;31:419-422.
36. Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005;3:1894-1904.
37. Collen D, Lijnen HR. Tissue-type plasminogen activator: a historical perspective and personal account. J Thromb Haemost 2004;2:541-546.
38. Lijnen HR. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001;86:324-333.
39. Welling TH, Huber TS, Messina LM, Stanley JC. Tissue plasminogen activator increases canine endothelial cell proliferation rate through a plasmin-independent, receptor-mediated mechanism. J Surg Res 1996;66:36-42.
40. Gravanis I, Tsirka SE. Tissue plasminogen activator and glial function. Glia 2005;49:177-183.
41. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 1998;4: 228-231.
42. Fredriksson L, Li H, Fieber C, Li X, Eriksson U. Tissue plasminogen activator is a potent activator of PDGF-CC. Embo J 2004;23:3793-3802.
43. Canbay A, Feldstein A, Baskin-Bey E, Bronk SF, Gores GJ. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. J Pharmacol Exp Ther 2004;308:1191-1196.
44. Zhaodong L, Mizuno S, Nakamura T. Anti-necrotic and anti-apoptotic effects of hepatocyte growth factor on cholestatic hepatitis in a mouse model of bile-obstructive diseases. Am J Physiol Gastrointest Liver Physiol 2007;292:G639-G646.
45. Marshall LJ, Ramdin LS, Brooks T, Charlton P, Shute JK. Plasminogen activator inhibitor-1 supports IL-8-mediated neutrophil transendothelial migration by inhibition of the constitutive shedding of endothelial IL-8/ heparan sulfate/syndecan-1 complexes. J Immunol 2003;171:2057-2065.
46. Flick MJ, Du X, Witte DP, Jirouskova M, Soloviev DA, Busuttil SJ, et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor alphaM-beta2/Mac-1 is critical for host inflammatory response in vivo. J Clin Invest 2004;113:1596-1606.
47. Mosesson MW, Siebenlist KR, Voskuilen M, Nieuwenhuizen W. Evaluation of the factors contributing to fibrin-dependent plasminogen activation. Thromb Haemost 1998;79:796-801.
48. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, et al. Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. Embo J 1990;9:467-474.
49. Blasi F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol Today 1997;18:415-417.
50. Miranda-Diaz A, Rincon AR, Salgado S, Vera-Cruz J, Galvez J, Islas MC, et al. Improved effects of viral gene delivery of human uPA plus biliodigestive anastomosis induce recovery from experimental biliary cirrhosis. Mol Ther 2004;9:30-37.
51. Barazzone C, Belin D, Piguet PF, Vassalli JD, Sappino AP. Plasminogen activator inhibitor-1 in acute hypetoxic mouse lung injury. J Clin Invest 1996;98:2666-2673.
52. Swaisgood CM, French EL, Noga C, Simon RH, Ploplis VA. The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system. Am J Pathol 2000;157:177-187.
53. Kitching AR, Holdsworth SR, Ploplis VA, Plow EF, Collen D, Carmeliet P, et al Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis. J Exp Med 1997;185:963-968.
54. Bezerra JA, Currier AR, Melin-Aldana H, Sabla G, Bugge TH, Kombrinck KW, et al. Plasminogen activators direct reorganization of the liver lobule after acute injury. Am J Pathol 2001;158:921-929.